MENU

Can Hims & Hers Health (HIMS) Stock Reach $31?

a company, which is involved in real estate investment trusts

A.I.Advisor
published price charts
A.I.Advisor
Nov 09, 2026

Can Hims & Hers Health (HIMS) Stock Reach $31?

Key Takeaways

  • The central price target of $31 is the arithmetic mean of the verified analyst targets reviewed, closely matching the widely cited S&P Global average of roughly $31 across 15 analysts.
  • At a latest verified close near $22.94, HIMS would need to climb roughly 35% to reach $31 — a very large move.
  • The analyst target range is unusually wide, from about $23 to $42, reflecting deep disagreement over the company's weight-loss opportunity and its deteriorating profit margins.
  • Key supports include rapid revenue growth (up about 49% year over year in the third quarter), nearly 2.8 million subscribers, and branded GLP-1 partnerships with Eli Lilly and Novo Nordisk.
  • The biggest risks are gross-margin compression, a third-quarter loss versus an expected profit, lowered 2026 EBITDA guidance, and regulatory and legal overhangs, including an FTC lawsuit.
  • For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, visit these dedicated pages.
  • Explore Trending AI Robots to see how AI-driven trading tools are tracking opportunities across the market.

Analyst Price Targets and Consensus View

Hims & Hers Health, Inc. is a telehealth platform that connects consumers to licensed healthcare professionals across the United States and internationally. The $31 central target is the arithmetic mean of current analyst targets and is broadly consistent with the average one-year price target of about $31 reported by S&P Global across 15 analysts.

Individual targets remain tightly clustered but tell a mixed story. Recent verified marks include Barclays at $35, Bank of America and Truist each at $32, J.P. Morgan at $32, Jefferies at $31, TD Cowen at $30, and Deutsche Bank at $26. The overall range spans roughly $23 to $42, a spread that underscores how differently analysts view the same business.

Sentiment has shifted repeatedly. Citigroup and Bank of America lifted their ratings from Sell and Underperform to Neutral in March, while J.P. Morgan initiated coverage with an Overweight stance. Barclays has trimmed its target from $39 to $35, and Morgan Stanley previously cut its mark sharply to $21. Most firms carry a Hold-equivalent rating, with a small minority still at Buy.

Current Market Position and Path Toward the Target

With the stock near $22.94 after a sharp selloff in early November 2026, reaching $31 would require a gain of roughly 35%. That qualifies as a very large move relative to the stock's recent trading history.

The path toward the target runs through the company's ability to show that its fast-growing weight-loss business can generate durable profit. Revenue grew about 49% year over year in the third quarter to roughly $890 million, and subscribers reached nearly 2.8 million. Yet the same quarter produced a loss of about $0.14 per share against expectations for a small profit, and gross margin fell sharply as lower-margin GLP-1 revenue displaced the company's historically high-margin offerings. Management also narrowed and lowered its full-year adjusted EBITDA guidance, which pressured the shares.

What Could Support a Move Toward the Target

  • Rapid top-line growth driven by weight loss, with international revenue expanding at a triple-digit pace.
  • Branded partnerships with Eli Lilly and Novo Nordisk that reduce reliance on compounded GLP-1 products and widen the addressable market.
  • New offerings, including testosterone treatments and an AI-powered women's health app, that broaden the product mix.
  • A relatively strong cash position and continued subscriber growth supporting long-term revenue visibility.

What Could Prevent the Target From Being Reached

  • Structural gross-margin compression as pharmacy-like GLP-1 sales replace higher-margin telehealth revenue.
  • A return to losses and lowered 2026 EBITDA guidance, which undermines the profitability narrative.
  • Regulatory and legal risk, including an FTC lawsuit alleging privacy violations and deceptive billing, FDA scrutiny of compounded GLP-1 drugs, and several securities investigations.
  • Intense competition in weight loss from branded drugs and pricing pressure, plus a high short interest of roughly 25% of float and a beta near 2.5 that amplifies volatility.

Technical Levels and Market Structure

The stock trades within a wide 52-week range of roughly $13.74 to $42.70. The area near $23 is emerging as a near-term support zone following the November decline, while the prior close near $26 and the $30-to-$32 band — where several analyst targets sit — represent overhead resistance. The $42.70 52-week high marks a major longer-term ceiling that the shares would need to clear before approaching levels consistent with the most optimistic targets.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ. Investors should watch quarterly earnings and guidance, gross-margin trends, subscriber and GLP-1 transaction data, analyst target revisions, and regulatory decisions from the FDA and FTC. Updates on the branded drug partnerships and any resolution of the outstanding legal investigations will also be important.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than scanning charts manually. For a fast-moving name like Hims & Hers, automated signal tracking can help identify shifts in momentum before they are widely recognized.

Final Assessment

The $31 target — the average of current analyst marks, with a range near $23 to $42 — sits about 35% above the recent price, making it a demanding objective. Reaching it would likely require the company to reverse margin compression, return to profitability, and resolve regulatory and legal uncertainties while sustaining rapid revenue growth. The wide dispersion among analysts reflects genuine uncertainty about whether the weight-loss pivot ultimately expands or erodes earnings power. The target is a reference point, not a forecast, and the balance of evidence leaves the outcome genuinely open.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

HIMS and Stocks

Correlation & Price change

A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIMS
1D Price
Change %
HIMS100%
-8.86%
COTY - HIMS
31%
Poorly correlated
-2.47%
HROW - HIMS
29%
Poorly correlated
-5.35%
AYTU - HIMS
28%
Poorly correlated
N/A
DERM - HIMS
25%
Poorly correlated
-7.04%
IRWD - HIMS
25%
Poorly correlated
-0.21%
More

Groups containing HIMS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIMS
1D Price
Change %
HIMS100%
-8.86%
Pharmaceuticals: Generic
industry (81 stocks)
14%
Poorly correlated
-3.61%
Pharmaceuticals
industry (151 stocks)
12%
Poorly correlated
-3.32%